国产精品自拍视频免费,国产精品爆乳在线播放

卡達唑胺

NMR下載 COA and HPLC MSDS下載
names：
Cadazolid
CAS號：
1025097-10-2
MDL Number：
MF(分子式)： C29H29F2N3O8 MW(分子量)： 585.55
EINECS: Reaxys Number:
Pubchem ID:44242317 Brand:BIOFOUNT

卡達唑胺(1025097-10-2,ACT-179811,Cadazolid)是一種新的惡唑烷酮類抗生素，對艱難梭菌具有有效的活性。

貨品編碼	規(guī)格	純度	價格 (￥)	現價(￥)	特價(￥)	庫存描述	數量	總計 (￥)
YZM000084-5mg	5mg	97.44%	￥ 1072.50	￥ 1072.50		2-3天	- +	￥ 0.00

大包裝詢價提供各種包裝，敬請垂詢
收藏商品商品點評加入購物車立即購買

快速詢價

收起

你想詢價的產品

*產品名稱：

CAS號：

產品編號：

需求描述：

請準確填寫您的聯(lián)系方式，以便為您提供最好的服務。

*公司名稱：

*電子郵箱：

聯(lián)系人：

*電話：

*驗證碼：

詢價

中文別名	卡達唑胺(1025097-10-2);卡達唑利德;卡達唑烷;
英文別名	Cadazolid(1025097-10-2);Cadazolid;ACT 179811;ACT179811;ACT-179811;ACT-179811; ACT 179811; ACT179811; CADAZOLID.;Cadazolid (ACT-179811);CS-2475;
CAS號	1025097-10-2
Inchi	InChI=1S/C29H29F2N3O8/c30-21-10-19-23(33(16-1-2-16)13-20(26(19)36)27(37)38)11-24(21)32-7-5-29(40,6-8-32)15-41-25-4-3-17(9-22(25)31)34-12-18(14-35)42-28(34)39/h3-4,9-11,13,16,18,35,40H,1-2,5-8,12,14-15H2,(H,37,38)/t18-/m1/s1
InchiKey	XWFCFMXQTBGXQW-GOSISDBHSA-N
分子式 Formula	C29H29F2N3O8
分子量 Molecular Weight	585.55
溶解度Solubility	生物體外In Vitro:DMSO溶解度≥ 150 mg/mL(256.17 mM)*"≥" means soluble可溶, but saturation unknown溶解度未知.
性狀	固體粉末,Power
儲藏條件 Storage conditions	-20°C , 存放在陰涼干燥處,3 years年 4°C 2 years年 / In solvent溶液中:-80°C 6 months月 -20°C 1 month月

卡達唑胺(1025097-10-2,ACT-179811,Cadazolid)實驗注意事項：
1.實驗前需戴好防護眼鏡，穿戴防護服和口罩，佩戴手套，避免與皮膚接觸。
2.實驗過程中如遇到有毒或者刺激性物質及有害物質產生，必要時實驗操作需要手套箱內完成以免對實驗人員造成傷害
3.實驗后產生的廢棄物需分類存儲，并交于專業(yè)生物廢氣物處理公司處理，以免造成環(huán)境污染Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.

Tags:卡達唑胺試劑,卡達唑胺雜質,卡達唑胺中間體,卡達唑胺合成,卡達唑胺溶解度,卡達唑胺旋光度,卡達唑胺密度,卡達唑胺閃點,卡達唑胺結構式,卡達唑胺購買，

產品說明	卡達唑胺(1025097-10-2,ACT-179811,Cadazolid)是一種有效的新的惡唑烷酮類抗生素，對Clostridium difficile具有有效的活性
Introduction	卡達唑胺(1025097-10-2,ACT-179811,Cadazolid)is a new oxazolidinone antibiotic with potent activity againstClostridium difficile.
Application1	卡達唑胺，也稱為ACT-179811，是一種新的氟喹諾酮惡唑烷酮抗生素，對艱難梭菌具有有效活性。
Application2
Application3

卡達唑胺(1025097-10-2,ACT-179811,Cadazolid)藥理學：

卡達唑胺是惡唑烷酮類抗生素，對革蘭氏陽性細菌（包括艱難梭菌）具有活性。盡管尚未完全闡明卡達唑利德發(fā)揮作用的確切作用方式，但在給藥時，該藥物抑制細菌蛋白質的合成并導致細菌細胞死亡。卡達唑利德已用于研究艱難梭菌感染治療的試驗中。

警示圖
危險性	warning
危險性警示	Not available
安全聲明	H303吞入可能有害+H313皮膚接觸可能有害+H2413吸入可能對身體有害
安全防護	P264處理后徹底清洗+P280戴防護手套/穿防護服/戴防護眼罩/戴防護面具+P305如果進入眼睛+P351用水小心沖洗幾分鐘+P338取出隱形眼鏡（如果有）并且易于操作,繼續(xù)沖洗+P337如果眼睛刺激持續(xù)+P2393獲得醫(yī)療建議/護理
備注	實驗過程中防止吸入、食入，做好安全防護

Baldoni D, et al. Cadazolid, a novel antibiotic with potent activity against Clostridium difficile: safety, tolerability and pharmacokinetics in healthy subjects following single and multiple oral dos

Chilton CH, et al. In vitro activity of cadazolid against clinically relevant Clostridium difficile isolates and in an in vitro gut model of C. difficile infection. J Antimicrob Chemother. 2014 Mar;69

Cadazolid for the treatment of Clostridium difficile PMID 28286992; Expert opinion on investigational drugs 2017 Apr; 26(4):509-514 (Review Article) Name matches: surotomycin cadazolid

Novel Antimicrobials for the Treatment of Clostridium difficile Infection PMID 29713630; Frontiers in medicine 2018; 5(?):96 (Review Article) Name matches: surotomycin cadazolid

Management of adult Clostridium difficile digestive contaminations: a literature review PMID 30498879; European journal of clinical microbiology & infectious diseases : official publication of the Eur

卡達唑胺(1025097-10-2,ACT-179811,Cadazolid)參考文獻：

1.Novel Antimicrobials for the Treatment of
Petrosillo N;Granata G;Cataldo MA Front Med (Lausanne). 2018 Apr 16;5:96. doi: 10.3389/fmed.2018.00096. eCollection 2018.

The current picture of ;Clostridium difficile; infection (CDI) is alarming with a mortality rate ranging between 3% and 15% and a CDI recurrence rate ranging from 12% to 40%. Despite the great efforts made over the past 10 years to face the CDI burden, there are still gray areas in our knowledge on CDI management. The traditional anti-CDI antimicrobials are not always adequate in addressing the current needs in CDI management. The aim of our review is to give an update on novel antimicrobials for the treatment of CDI, considering the currently available evidences on their efficacy, safety, molecular mechanism of action, and their probability to be successfully introduced into the clinical practice in the near future. We identified, through a PubMed search, 16 novel antimicrobial molecules under study for CDI treatment: cadazolid, surotomycin, ridinilazole, LFF571, ramoplanin, CRS3123, fusidic acid, nitazoxanide, rifampin, rifaximin, tigecycline, auranofin, NVB302, thuricin CD, lacticin 3147, and acyldepsipeptide antimicrobials. In comparison with the traditional anti-CDI antimicrobial treatment, some of the novel antimicrobials reviewed in this study offer several advantages, i.e., the favorable pharmacokinetic and pharmacodynamic profile, the narrow-spectrum activity against CD that implicates a low impact on the gut microbiota composition, the inhibitory activity on CD sporulation and toxins production.

2.[New antibacterial agents on the market and in the pipeline].
Kern WV Internist (Berl). 2015 Nov;56(11):1255-63.

After some years of stagnation there have been several new successful developments in the field of antibacterial agents. Most of these new developments have been in conventional antibacterial classes. New drugs among the beta-lactam agents are methicillin-resistant Staphylococcus aureus (MRSA) active cephalosporins (ceftaroline and ceftobiprole) and new combinations of beta-lactam with beta-lactamase inhibitors (ceftolozane/tazobactam, ceftazidime/avibactam, imipenem/relebactam and meropenem/RPX7009). New developments can also be observed among oxazolidinones (tedizolid, radezolid, cadazolid and MRX-I), macrolides/ketolides (modithromycin and solithromycin), aminoglycosides (plazomicin), quinolones (nemonoxacin, delafloxacin and avarofloxacin), tetracyclines (omadacycline and eravacycline) as well as among glycopeptides and lipopeptides (oritavancin, telavancin, dalbavancin and surotomycin). New agents in a very early developmental phase are FabI inhibitors, endolysines, peptidomimetics, lipid A inhibitors, methionyl-tRNA synthetase inhibitors and teixobactin.

3.[Treatment of acute and recurrent Clostridium difficile infections : What is new?]
von Braun A;Lübbert C Internist (Berl). 2018 May;59(5):505-513. doi: 10.1007/s00108-018-0401-x.

The incidence of clostridium difficile infections (CDI) remains on a high level globally. In Germany, the number of severe or even lethal cases continues to increase. The main risk factor for the development of CDI is exposure to broad spectrum antibiotics, which disturb the physiological microbiome and therefore enable colonization with C. difficile. According to the updated US and European guidelines, orally administered vancomycin is the treatment of choice. Fidaxomicin is as effective as vancomycin but has the advantage of a lower rate of recurrence. Furthermore, recent clinical studies were able to demonstrate that significantly fewer recurrences occurred in patients who additionally received the monoclonal antibody bezlotoxumab. In recent years, several new antibiotics with narrow-spectrum acitivity and low intestinal resorption have been developed for the treatment of CDI, including surotomycin, cadazolid, and ridinilazol. Novel toxoid vaccines are expected to become an efficacious tool in the prevention of CDI; however, pivotal clinical trials have so far not been completed.

對不起，暫無產品評價！

MSDS

SDS 1.0 中文

展開

SDS 1.0 英文

展開